Diabetic macular edema market set to more than double by 2031
Driven by the launch of longer-acting anti-vascular endothelial growth factor (VEGF) therapies among other pioneering pipeline therapies, the diabetic macular edema market is expected to more than double over the next decade.
The DME market in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $5.0 billion in 2021 to $11.1 billion in 2031, data and analytics firm GlobalData has forecast.
According to GlobalData, the growth will be supported by the US Food and Drug Administration (FDA) approval of Roche’s (ROG: SIX) Vabysmo (faricimab) for DME in January 2022, coupled with the anticipated approval of other longer-acting anti-VEGF pipeline therapies, and the new mechanisms of action to the DME space, during the forecast period. The drug also gained approval in Europe this week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze